OC
TGTX icon

Oppenheimer & Co’s TG Therapeutics TGTX Stock Holding History

Oppenheimer & Co’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32,470
Closed -$759K – 1644
2024
Q3 		$759K Buy
+32,470
New +$709K 0.01% 887
2021
Q3 		– Sell
-5,400
Closed -$209K – 1572
2021
Q2 		$209K Sell
5,400
-5,700
-51% -$224K ﹤0.01% 1406
2021
Q1 		$535K Buy
+11,100
New +$533K 0.01% 938

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Oppenheimer & Co's TGTX Position: Q4 2024 in Review

Oppenheimer & Co sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 32,470 shares — an estimated $759K sold.

Oppenheimer & Co first reported a position in TGTX in Q1 2021 and held it in 3 quarters. The position peaked at $759K in Q3 2024. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Oppenheimer & Co reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Oppenheimer & Co sold 32,470 TG Therapeutics shares in Q4 2024, an estimated $759K.
  • Oppenheimer & Co first reported a position in TG Therapeutics in Q1 2021 and held it in 3 quarters.
  • Oppenheimer & Co's TG Therapeutics position peaked at $759K in Q3 2024.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Oppenheimer & Co's 13F filing for Q4 2024, filed 5 Feb 2025.